Application of bifidobacterium breve H4-2 exopolysaccharide in relieving mouse intestinal injury caused by OVA

The extracellular polysaccharide EPS-1 extracted and purified from Bifidobacter brevis H4-2 was solved, and the intestinal damage caused by OVA allergy was significantly alleviated. The allergic reactions and intestinal inflammation in mice were significantly reduced, and the intestinal barrier was repaired. , regulates the immune response and intestinal microbiota, and achieves the maintenance of intestinal microbial homeostasis.

CN119033807APending Publication Date: 2024-11-29NORTHEAST AGRICULTURAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411175330.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing treatments have limited effects on intestinal damage caused by allergic ovalbumin (OVA), and have great impact on lifestyle and potential side effects, and lack natural, non-toxic and effective treatment options.

Method used

Extracellular polysaccharide EPS-1 extracted from Bifidobacter brevis H4-2 and purified by DEAE-Cellulose 52 and Sepharose CL-6B were used to alleviate intestinal damage caused by OVA, regulate immune responses and intestinal microbial populations , repair the intestinal barrier.

Benefits of technology

EPS-1 significantly reduced OVA-induced weight loss, diarrhea and allergic reactions in mice, restored intestinal barrier integrity, regulated immune cell differentiation and factor levels, increased intestinal flora diversity, reduced inflammation, and maintained intestinal microbial stability state.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention discloses an application of mannose-rich exopolysaccharide separated from bifidobacterium breve H4-2 in preparation of a medicine for relieving mouse intestinal injury caused by OVA (ovalbumin A). The invention provides a new application of bifidobacterium breve H4-2 exopolysaccharide, EPS-1 intervention can effectively relieve mouse anaphylaxis caused by OVA, and the intestinal physical barrier is improved by increasing mucoprotein content and goblet cell count in mouse ileum tissue. Moreover, the EPS-1 intervention maintains the integrity of the immune barrier by restoring the unbalanced CD4 + T / CD8 + T ratio, modulating Th1 / Th2 and Th17 / Treg cell balance, and inhibiting the activation of the NF-[kappa] B signaling pathway. In addition, the EPS-1 intervention maintains the homeostasis in the intestinal microbiota barrier by increasing the abundance of the Ruminococcus, the abundance of the Butyricaceae and the abundance of the Muracaceae, and at the same time, the abundance of the Streptococcus and the abundance of the Candidate Arthromycin are reduced, so that the homeostasis in the intestinal microbiota barrier is maintained. Finally, the EPS-1 indirectly relieves intestinal injury induced by OVA by increasing the content of metabolites such as tyrosine, methionine, tryptophan, triglyceride and salidroside.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of food microorganisms and immune regulation, and mainly relates to the use of Bifidobacterium breve H4-2 extracellular polysaccharide in alleviating OVA-induced intestinal damage in mice. Background Art

[0002] Maintaining intestinal homeostasis is crucial to the occurrence and development of intestinal diseases. A strong intestinal barrier can effectively resist external factors.

[0003] Food allergy refers to an adverse immune response triggered by specific ingredients in food. Physiological dysfunction or tissue damage caused by food ingestion can lead to a series of allergic clinical symptoms, including vomiting, abdominal pain and diarrhea. Ovalbumin (OVA) is a major protein found in egg white and is one of the main allergens causing egg white allergy. In recent years, the morbidity and mortality of intestinal immune diseases related to OVA allergy have continued to rise. Current treatments mainly include avoiding allergens and antihistamine intervention. Although these methods have certain therapeutic effects, they can significantly affect an individual's lifestyle, causing inconvenience, and also have potential adverse side effects. Therefore, it is imperative to study natural, non-toxic and effective substances to improve OVA allergy.

[0004] Bifidobacteria are the main bacterial groups naturally present in the gastrointestinal tract and have been extensively studied for their roles in maintaining the balance of intestinal microbiota, reducing serum cholesterol levels and lipid concentrations, and stimulating the body's immune response. Studies have shown that bifidobacterial exopolysaccharides (EPSs) have antioxidant, immunomodulatory, and colitis repair effects. EPSs isolated from bifidobacteria have been shown to have the potential to alleviate intestinal damage caused by food allergies. For example, EPSs from Bifidobacterium longum modulated allergic responses in mice through Toll-like receptor-2 (TLR-2) signaling activation, while inhibiting eosinophil proliferation and IL-4 / IL-13 gene expression. EPSs isolated from Bifidobacterium breve WBBR04 effectively sequestered allergens by enhancing intestinal barrier integrity, thereby preventing food allergies. Although these findings confirm that bifidobacterial EPS can alleviate allergic bowel diseases, a comprehensive understanding of the effects of Bifidobacterium breve EPSs on allergic bowel diseases and intestinal barrier damage is still needed.

[0005] Previous studies have found that EPSs isolated from Bifidobacterium breve H4-2 have the effect of repairing the intestinal barrier. EPS-1 produced by H4-2 is a mannose-rich polysaccharide component with immunomodulatory activity. In order to comprehensively study the role and mechanism of EPS-1 in alleviating intestinal damage caused by OVA allergy, an intestinal mucosal injury model of OVA-allergic mice was constructed to further explore the specific effect of EPS-1 on the intestinal immune barrier and its effect on the intestinal microbiota. Summary of the invention

[0006] The present invention aims to provide a use of Bifidobacterium breve H4-2 exopolysaccharide in alleviating intestinal damage caused by OVA in mice. It is characterized in that the exopolysaccharide is extracted from the fermentation broth of Bifidobacterium breve H4-2, and then purified using a DEAE-Cellulose 52 anion exchange column and Sepharose CL-6B to obtain the EPS-1 component, and the Bifidobacterium breve H4-2 is deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration, Beijing, with a deposit number of CGMCC No.31450 and a deposit date of July 25, 2024.

[0007] The EPS-1 alleviated OVA-induced weight loss, diarrhea and allergic reactions in mice.

[0008] The EPS-1 can reduce the inflammatory infiltration of mouse ileum tissue, restore the integrity of the ileum to varying degrees, increase the expression of goblet cells and mucin MUC2, and repair the damage to the intestinal physical barrier of mice caused by OVA.

[0009] The EPS-1 can inhibit the degranulation of mouse ileal mast cells induced by OVA, reduce the number of mast cells and the expression of IgE, and restore the unbalanced CD4+T / CD8+T ratio.

[0010] The EPS-1 can inhibit the differentiation of CD4+T cells into Th2 and Th17 cells, and promote the differentiation of CD4+T cells into Th1 and Treg cells.

[0011] The EPS-1 regulates the levels of related cytokines, increases the content of TGF-β and INF-γ in the ileum tissue of mice, and significantly reduces the content of HIS, IgE, IL-4, IL-17A, IL-6, IL-1β and TNF-α.

[0012] The EPS-1 can inhibit the expression of NF-κB signaling pathway and alleviate intestinal inflammation caused by OVA.

[0013] EPS-1 increases the diversity and richness of the intestinal flora of mice and reduces Streptococcus and Candidatus_Arthromitus The relative abundance of Lachnospiraceae , Alistipes , Bacteroides , Muribaculaceae , Ruminococcus as well as Butyricicoccus The relative abundance of acetic acid, propionic acid, butyric acid and valeric acid increased, maintaining intestinal microbial homeostasis.

[0014] The EPS-1 can regulate tyrosine metabolism (map00350), tryptophan metabolism (map00380), anthocyanin biosynthesis (map00942), secondary bile acid biosynthesis (map00121), methionine metabolism (map00270)

[0015] and cholesterol metabolism (map04979), increasing the contents of short-chain fatty acids, amino acids, azelaic acid, tributyrin, salidroside, and myristic acid repaired the intestinal barrier damage of mice caused by OVA. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative work.

[0017] Figure 1 Effects of EPS-1 on mouse body weight (A), allergy index (B), diarrhea index (C), spleen appearance (D), thymus appearance (E) and organ index (F);

[0018] Figure 2 The changes of small intestinal appearance (A), length (B), HE staining (C), AB-PSA staining (D), histopathological score (E), goblet cell number (F) and MUC2 mRNA expression (G) in mice after EPS-1 intervention;

[0019] Figure 3 Effects of EPS-1 on mast cell expression (A), mast cell degranulation percentage (B), IgE expression (C), IgE percentage (D), CD4+T and CD8+T cell expression (E), CD4+T cell score (F), CD8+T cell score (G), and CD4+ / CD8+ ratio (H) in mouse ileum;

[0020] Figure 4 The results show the differentiation of CD4+T cells (A) and the percentages of Treg cells (B), Th1 cells (C), Th2 cells (D) and Th17 cells (E) in the ileal lymph nodes of mice after EPS-1 intervention.

[0021] Figure 5 Effects of EPS-1 intervention on the levels of HIS (A), IgE (B), IL-4 (C), IL-17A (D), TGF-β (E), INF-γ (F), IL-6 (G), IL-1β (H), and TNF-α (I) in the ileum of mice;

[0022] Figure 6 The protein electrophoresis diagrams of CD4+ cell differentiation-related proteins (A) and NF-κB signaling pathway-related proteins (B) in the ileum of mice after EPS-1 intervention, as well as the expression levels of CD4+ cell differentiation-related proteins (C), NF-κB signaling pathway-related proteins (D) and related mRNA gene expression (E);

[0023] Figure 7 The changes in the abundance of intestinal microbiota (A), Alpha diversity index (B), relative abundance at the phylum level (C), and relative abundance at the genus level (D) of mice after EPS-1 intervention, as well as the effects of EPS-1 on the levels of short-chain fatty acids (SCFA) in the intestine of mice, including acetate (E), propionate (F), butyrate (G), and valerate (H);

[0024] Figure 8 Bubble diagram of horizontal metabolic pathways between NC and MC (A) and between MC and H-EPS-1 (B); KEGG network diagram of differential metabolites and pathways (C), heat map of abundant metabolites (D), correlation between intestinal flora and metabolites (E), and Spearman correlation analysis (F); DETAILED DESCRIPTION

[0025] The specific embodiments of the present invention are described in detail below with reference to the accompanying drawings.

[0026] The use of Bifidobacterium breve H4-2 exopolysaccharide in alleviating OVA-induced intestinal damage in mice. It is characterized in that the exopolysaccharide is extracted from the fermentation broth of Bifidobacterium breve H4-2, and then purified using DEAE-Cellulose 52 anion exchange column and Sepharose CL-6B to obtain the EPS-1 component. The Bifidobacterium breve H4-2 is deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration, Beijing, with a deposit number of CGMCC No. 31450 and a deposit date of July 24, 2024.

[0027] The EPS-1 alleviated OVA-induced weight loss, diarrhea and allergic reactions in mice.

[0028] The EPS-1 can reduce the inflammatory infiltration of mouse ileum tissue, restore the integrity of the ileum to varying degrees, increase the expression of goblet cells and mucin MUC2, and repair the damage to the intestinal physical barrier of mice caused by OVA.

[0029] The EPS-1 can inhibit the degranulation of mouse ileal mast cells induced by OVA, reduce the number of mast cells and the expression of IgE, and restore the unbalanced CD4+T / CD8+T ratio.

[0030] The EPS-1 can inhibit the differentiation of CD4+T cells into Th2 and Th17 cells, and promote the differentiation of CD4+T cells into Th1 and Treg cells.

[0031] The EPS-1 regulates the levels of related cytokines, increases the content of TGF-β and INF-γ in the ileum tissue of mice, and significantly reduces the content of HIS, IgE, IL-4, IL-17A, IL-6, IL-1β and TNF-α.

[0032] The EPS-1 can inhibit the expression of NF-κB signaling pathway and alleviate intestinal inflammation caused by OVA.

[0033] The EPS-1 increases the diversity and richness of the intestinal flora in mice, reduces the relative abundance of Streptococcus and Candidatus_Arthromitus, increases the relative abundance of Lachnospiraceae, Alistipes, Bacteroides, Muribaculaceae, Ruminococcus and Butyricicoccus, and increases the levels of acetate, propionate, butyrate and valerate, thereby maintaining intestinal microbial homeostasis.

[0034] The EPS-1 can regulate tyrosine metabolism (map00350), tryptophan metabolism (map00380), anthocyanin biosynthesis (map00942), secondary bile acid biosynthesis (map00121), methionine metabolism (map00270)

[0035] and cholesterol metabolism (map04979), increasing the contents of short-chain fatty acids, amino acids, azelaic acid, tributyrin, salidroside, and myristic acid repaired the intestinal barrier damage of mice caused by OVA.

[0036] Example 1

[0037] The EPS-1 fraction purified in this study was initially extracted from the fermentation broth of Bifidobacterium breve H4-2 and subsequently purified using a DEAE-Cellulose 52 anion exchange column and Sepharose CL-6B. The extraction and purification methods are described in “MM Niu, HX Guo, JC Shang, XC Meng, Structural Characterization and Immunomodulatory Activity of a Mannose-Rich Polysaccharide Isolated from Bifidobacterium breve H4-2, J. Agric. Food Chem. 71 (2023) 19791-19803.”

[0038] Example 2

[0039] BALB / c mice (n=40, 6-week-old male mice) were purchased from Charles River Laboratory Animal Technology Co., Ltd. and evenly divided into five groups (n=8 in each group): normal group (NC), model group (MC), low EPS-1 (100 mg / kg.d) dose group (L-EPS-1), medium EPS-1 (200 mg / kg.d) dose group (M-EPS-1), and high EPS-1 (400 mg / kg.d) dose group (H-EPS-1). The specific model establishment process was two intraperitoneal injections on the 0th and 14th days, and OVA was gavaged every other day from the 21st day, for a total of 5 times. At the same time, different concentrations of EPS-1 solutions were gavaged every day from the 15th day of the experiment, for a total of 14 days. The mice were euthanized by cervical dislocation 2 hours after the last OVA administration on the 29th day. The normal group received intraperitoneal injections and gavages of the same dose of normal saline. The protocol was approved by the Ethics Committee of Northeast Agricultural University (registration number: NEUEC20230439).

[0040] The body weight of mice was measured weekly, and allergy and diarrhea were observed and evaluated after the last administration.

[0041] On day 29 of the experiment, mice were euthanized by dislocation after eyeball blood sampling. The spleen,

[0042] thymus and ileum.

[0043] The results showed that EPS-1 alleviated OVA-induced weight loss, diarrhea and allergic reactions in mice. Figure 1 .

[0044] Example 3

[0045] After fixation, dewaxing, and paraformaldehyde embedding, ileum tissues were cut into 4 μm sections. Subsequently, these sections were stained with hematoxylin-eosin (H&E), alcian blue and periodic acid-Schiff (AB-PAS), and toluidine blue (TB). Images were captured and analyzed using a microscope with a Nikon DS-U3 imaging system.

[0046] The results showed that EPS-1 could reduce the inflammatory infiltration of mouse ileum tissue, restore the integrity of the ileum to varying degrees, increase the expression of goblet cells and mucin MUC2, and repair the damage to the intestinal physical barrier of mice caused by OVA. Figure 2 .

[0047] Example 4

[0048] After tissue sections were dewaxed, cleaned, and antigen retrieved, natural fluorescence quenchers were used for quenching. After blocking with BSA for 30 min, sections were incubated with IgE antibody (Abcam, 1:1000) overnight, and then the secondary antibody (Millipore,

[0049] Then, after DAPI nuclear staining, the images were taken using a Nikon DS-U3 imaging system.

[0050] Observe and capture images.

[0051] Similar to the immunofluorescence assay process, tissue sections were treated with antigen retrieval, and then, after successful dewaxing and hydration steps, endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide solution. Then, the sections were blocked with BSA solution (1%) for 30 min, and then incubated with primary antibodies against CD4 (Abcam; 1:2000) or CD8 (Abcam: 1:2000) overnight at 4 °C. After washing three times with 2% PBST, the slides were incubated with secondary antibodies for 1 h. After DAB staining, the reaction was stopped with 2% PBT. Subsequently, the DAB-stained sections were restained with hematoxylin and dehydrated. The positive areas in these sections were observed under a microscope for analysis using Image J software.

[0052] The results showed that EPS-1 could inhibit the degranulation of mast cells in the mouse ileum induced by OVA, reduce the number of mast cells and the expression of IgE, and restore the imbalanced CD4+T / CD8+T ratio. Figure 3 .

[0053] Example 5

[0054] The PP node of the fresh mouse ileum and mesenteric mesenteric junction was surgically removed and rinsed with cold PBS to remove fecal contents. The cleaned tissue was quickly transferred to a centrifuge tube containing 10 mL RPMI 1640 medium (10% fetal bovine serum), 50 mg neutral protease, and 150 mg collagenase II. The mixture was then centrifuged at 1000g for 30 min at 37 °C. After digestion, the PP cells were filtered through a filter with a pore size of 40 μm. The filtered PP cells were then centrifuged at 1500r / min and kept at 4 °C for another 10 min, and then resuspended in 2 mL PBS for flow cytometric analysis.

[0055] The resuspended cell solution (100 μL) was incubated with CD25 (1 μg) (eBioscience, USA) and CD4 (1 μg)

[0056] (eBioscience, USA) antibodies. After mixing and staining for 30 min in the dark at 4 ℃, the mixed solution was permeabilized by adding the fixation permeabilization solution (500 μL) and then stained for another 40 min. Then, 1 mL of the permeabilization solution was added, followed by centrifugation at 400g for 5 min, and the supernatant was discarded. After repeated washing steps as described above, antibodies Foxp3 (eBioscience, USA), IL-17A (eBiosscience, USA), INF-γ (eBiosScience, USA), and IL-4 (eBiosSciences, USA) were added in sequence. After thorough mixing again, 400 μL of PBS was added to resuspend the cells, and then the cell distribution was detected using a ZE5 flow cytometer (Bio-rad, USA). Finally, data analysis was performed using Everest software.

[0057] The results showed that EPS-1 could inhibit the differentiation of CD4+T cells into Th2 and Th17 cells, and promote the differentiation of CD4+T cells into Th1 and Treg cells. Figure 4 .

[0058] Example 6

[0059] The levels of HIS, IgE, IL-4, IL-17A, TGF-β, INF-γ, IL-6, IL-1β, and TNF-α in mouse ileal tissues were detected using ELISA kits purchased from Chenglin Bioengineering Institute (Beijing, China).

[0060] The results showed that EPS-1 regulated the levels of related cytokines, increased the content of TGF-β and INF-γ in the ileum tissue of mice, and significantly reduced the content of HIS, IgE, IL-4, IL-17A, IL-6, IL-1β and TNF-α. Figure 5 .

[0061] Example 7

[0062] The total RNA was isolated using the FastPure Cell / Tissue Total RNA Isolation Kit V2 (Vazyme Biotech Co., Ltd., China

[0063] Total RNA was extracted from mouse ileum tissues in Nanjing. Reverse transcription was performed using the GoScript™ Reverse Transcription Mix Kit according to the manufacturer's instructions. Quantitative real-time PCR reactions were performed using the GoTaq® qPCR Master Mix Kit on the PikoReal 96 PCR System. GAPDH was used as the reference gene and 2 -ΔΔCt The relative mRNA expression levels of MUC2, ZO-1, Occludin, Claudin-1, NF-κB, IκBα, T-bet, Foxp3, GATA-3, and RORγt in mouse ileum tissue were calculated by the Primer 5.0 software and synthesized by Jilin Jiumei Biotechnology Co., Ltd.

[0064] The concentration of proteins extracted from ileal tissues was determined using a BCA assay kit (Beyotime Biotechnology, Shanghai, China). Briefly, equal amounts of protein samples (40 ug / mL) were separated by SDS-PAGE gel and transferred to PVDF membranes. After blocking with 3% BSA for 1 h at room temperature, the membranes were covered with primary antibodies (NF-κB, I-κB, GATA-3, T-bet, RORγT, Foxp3) overnight at 4 °C. After washing three times with TBST solution, the membranes were incubated with secondary antibodies for 30 min at room temperature. The visualization of protein bands was detected using an enhanced chemiluminescence analysis kit, and the density of the bands was analyzed by IPWIN60 software.

[0065] The results showed that EPS-1 could inhibit the expression of NF-κB signaling pathway and reduce intestinal inflammation caused by OVA. Figure 6 .

[0066] Example 8

[0067] The levels of short-chain fatty acids (SCFA) in intestinal contents were measured according to the method described in “X. Zheng, Y. Qiu, W. Zhong, S. Baxter, M. Su, A targetedmetabolomic protocol for short-chain fatty acids and branched-chain aminoacids, Metabolomics. 9 (2013) 818-827.” Briefly, the intestinal contents were diluted with double distilled water and mixed with sulfuric acid, cyclohexanone, and diethyl ether. The SCFA levels in the supernatant of this mixture were determined using gas chromatography-mass spectrometry (Shimadzu GCMS-QP2010 Ultra system). The carrier gas for detection was high-purity helium with a flow rate of 1.0 mL / min and a column temperature of 220 °C. The mass spectrometry system was an electron ion source. The temperature was 230 °C and the interface temperature was 220 °C.

[0068] Total bacterial DNA was extracted from feces using the Rapid DNA SPIN extraction kit (MP Biomedicals, USA). The bacterial 16S rRNA gene (V3-V4) was amplified using forward primer 338F (5'-AACTCTACGGGGGGAGCA-3') and reverse primer 806R (5'-GACACHVGGTTCTAAT-3'). Amplicons were purified, quantified, pooled, and sequenced using the Illumina MiSeq platform and MiSeq Detection Kit v3. Data were analyzed using QIME software (v1.8.0).

[0069] The results showed that EPS-1 increased the diversity and richness of the intestinal flora of mice and reduced S treptococcus and Candidatus_Arthromitus The relative abundance of Lachnospiraceae , Alistipes , Bacteroides , Muribaculaceae , Ruminococcus as well as Butyricicoccus The relative abundance of acetic acid, propionic acid, butyric acid and valeric acid increased, maintaining intestinal microbial homeostasis. Figure 7 .

[0070] Example 9

[0071] Liquid chromatography-mass spectrometry (LC-MS) was used to analyze the differences in metabolites in the intestinal contents of mice in the NC, MC, and H-EPS-1 groups. Briefly, 25 mg of sample was mixed with 800 μL of pre-cooled precipitant solution, which consisted of methanol: acetonitrile: pure water = 2:1:1. After thorough grinding and ultrasonic treatment in an ice bath for 10 min, the sample was centrifuged at 25000 g, 4 ° C for 15 min, and then 600 μL of supernatant was extracted and the process was repeated. The supernatant was then dried using a desiccator, reconstituted with 600 μL of 10% methanol solution, ultrasonicated in an ice bath for 10 min, and centrifuged for 15 min. Small molecules were separated using a chromatographic column equipped with ACQUITYUPLC HSS T3s (100 mm x 2.1 mm, 1.8 μm) HPLC, and the chromatographic parameters were column temperature 50 ° C, flow rate 0.4 mL / min, and injection volume 5 μL. The mobile phase consisted of phase A (water and 0.1% formic acid solution) and phase B (methanol and 0.1% formic acid aqueous solution). Subsequently, a high-resolution tandem mass spectrometer Xevo G2-XSQTOF was used to collect positive and negative ion modes of the separated small molecules. Progenesis QI (version 2.2) software was used to extract peaks from the raw mass spectrometry data to obtain differential information of different groups of metabolites.

[0072] The results showed that EPS-1 could repair the intestinal barrier damage of mice caused by OVA by regulating tyrosine metabolism (map00350), tryptophan metabolism (map00380), anthocyanin biosynthesis (map00942), secondary bile acid biosynthesis (map00121), methionine metabolism (map00270) and cholesterol metabolism (map04979), increasing the content of short-chain fatty acids, amino acids, azelaic acid, tributyrin, salidroside and myristic acid. Results are shown in Figure 8 .

Claims

1. Use of Bifidobacterium breve H4-2 exopolysaccharide in alleviating OVA-induced intestinal damage in mice, characterized in that: The exopolysaccharide was extracted from the fermentation broth of Bifidobacterium breve H4-2, and then purified using a DEAE-Cellulose 52 anion exchange column and Sepharose CL-6B to obtain the EPS-1 component. The Bifidobacterium breve H4-2 was deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration, Beijing, with a deposit number of CGMCC No.31450 and a deposit date of July 25, 2024.

2. The use according to claim 1, characterized in that: The EPS-1 alleviated OVA-induced weight loss, diarrhea and allergic reactions in mice.

3. The use according to claim 1, characterized in that: The EPS-1 can reduce the inflammatory infiltration of mouse ileum tissue, restore the integrity of the ileum to varying degrees, increase the expression of goblet cells and mucin MUC2, and repair the damage to the intestinal physical barrier of mice caused by OVA.

4. The use according to claim 1, characterized in that: The EPS-1 can inhibit the degranulation of mouse ileal mast cells induced by OVA, reduce the number of mast cells and the expression of IgE, and restore the unbalanced CD4+T / CD8+T ratio.

5. The use according to claim 1, characterized in that: The EPS-1 can inhibit the differentiation of CD4+T cells into Th2 and Th17 cells, and promote the differentiation of CD4+T cells into Th1 and Treg cells.

6. The use according to claim 1, characterized in that: The EPS-1 regulates the levels of related cytokines, increases the content of TGF-β and INF-γ in the ileum tissue of mice, and significantly reduces the content of HIS, IgE, IL-4, IL-17A, IL-6, IL-1β and TNF-α.

7. The use according to claim 1, characterized in that: The EPS-1 can inhibit the expression of NF-κB signaling pathway and alleviate intestinal inflammation caused by OVA.

8. The use according to claim 1, characterized in that: EPS-1 increases the diversity and richness of the intestinal flora of mice and reduces Streptococcus and Candidatus_Arthromitus The relative abundance of Lachnospiraceae , Alistipes , Bacteroides , Muribaculaceae , Ruminococcus as well as Butyricicoccus The relative abundance of acetic acid, propionic acid, butyric acid and valeric acid increased, maintaining intestinal microbial homeostasis.

9. The use according to claim 1, characterized in that: The EPS-1 can repair the intestinal barrier damage of mice caused by OVA by regulating tyrosine metabolism (map00350), tryptophan metabolism (map00380), anthocyanin biosynthesis (map00942), secondary bile acid biosynthesis (map00121), methionine metabolism (map00270) and cholesterol metabolism (map04979), increasing the content of short-chain fatty acids, amino acids, azelaic acid, tributyrin, salidroside and myristic acid.